Weight-Loss drugs may cause hidden anal issues, new study warns

NCT ID NCT07668765

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 100 people with severe obesity who are starting a GLP-1 drug (like Ozempic or Wegovy) to see if it causes new anal or rectal problems within the first 3 months. Participants will have a check-up before starting the drug and again after 3 months to look for issues like hemorrhoids, anal fissures, or changes in bowel habits. The goal is to better understand these side effects so doctors can help patients manage them.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GLP-1 receptor agonist (a class of diabetes/weight-loss drugs)
What this could lead to
If successful, this could help doctors understand and manage common anorectal side effects like constipation or hemorrhoids in people taking GLP-1 drugs for obesity.
What could go wrong
This is a small, early observational study with no control group. It only looks at short-term effects (3 months) and cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANORECTAL DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

constipation disorder diarrheal disease Drug-Related Side Effects and Adverse Reactions Fissure in Ano hemorrhoid morbid obesity Obesity rectal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gazi University Faculty of Medicine

    Ankara, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.